Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 29, 2013

Primary Completion Date

September 2, 2015

Study Completion Date

April 28, 2016

Conditions
Refractory Low-grade GliomasRecurrent Low-grade Gliomas
Interventions
DRUG

Nilotinib

Tasigna®(nilotinib):: 50 mg, 150 mg and 200 mg capsules. Tasigna® capsules contain lactose monohydrate, crospovidone, poloxamer, colloidal silicon dioxide and magnesium. Orally; the capsules should be swallowed as a whole with water. No food should be consumed for 2 hours before the dose is taken and for at least one hour thereafter. For patients who are unable to swallow capsules, the content of each capsule may be dispersed in one teaspoon of apple sauce or compote or nonfat plain yogurt and should be taken immediately. Not more than one teaspoon of apple sauce / yogourt, and no food other than apple sauce or nonfat plain yogurt must be used.

DRUG

Vinblastine

"Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle.~Each 28-day cycle is repeated on Day 29/Day 1. No intra-patient doseescalation is permitted. Dose allocation will be centrally defined, based on toxicity observed in patients previously evaluated. Every new patient will be treated at the best current recommended dose, i.e. the dose associated with an estimated level of toxicity that is judged acceptable (20% DLT). At least two patients fully observed with no DLT are requested at a given dose level before dose escalation."

Trial Locations (8)

3008

Swiss Pediatric Oncology Group, Bern

35128

University Hospital of Padua, Padua

94805

Gustave Roussy, Villejuif

A-1090

Medical University of Vienna, Vienna

DK - 2100

Rigshospitalet, Copenhagen

3015GJ

Erasmus MC/Sophia Children's Hospital, Rotterdam

08950

Fundació Sant Joan de Déu, Barcelona

B15 2TT

Cancer Research UK Clinical Trials Unit School of Cancer Sciences University of Birmingham, Edgbaston

All Listed Sponsors
lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

NCT01884922 - Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults | Biotech Hunter | Biotech Hunter